


Fig. S6



Supplementary Fig. S6. Targeting MCT-1 and tocilizumab treatment together suppress 4T1 cancer stemness. MCT-1 (A), CD133 (B), Snail1 (C), Nanog (D) and Oct-4 (E) mRNA levels in the 4T1 mammospheres were evaluated after tocilizumab (200 $\mu\text{g}/\text{ml}$) treatment for 9 days. The results are expressed as the mean \pm SD (n=3). (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$).